Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2992 |
Name | prostate neuroendocrine neoplasm |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate neuroendocrine neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
KIT positive | Imatinib | prostate neuroendocrine neoplasm | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01799278 | Phase II | Alisertib | A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer | Completed | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT03582475 | Phase I | Etoposide Carboplatin + Docetaxel + Etoposide + Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | Active, not recruiting | USA | 0 |
NCT03837353 | Phase Ib/II | DKN-01 DKN-01 + Docetaxel | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | Terminated | USA | 0 |
NCT03910660 | Phase Ib/II | Pembrolizumab + Talabostat mesylate | A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer | Active, not recruiting | USA | GBR | 0 |
NCT04090775 | Phase II | Cyclophosphamide + Ipilimumab + Nivolumab | A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma | Completed | USA | 0 |
NCT04179864 | Phase I | Enzalutamide + Tazemetostat Abiraterone + Prednisone + Tazemetostat | A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ESP | BEL | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Recruiting | USA | 0 |
NCT04702737 | Phase I | Tarlatamab | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Completed | USA | NLD | GBR | FRA | ESP | BEL | AUT | AUS | 1 |
NCT04709276 | Phase II | Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) | Recruiting | USA | 0 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT05268666 | Phase Ib/II | JBI-802 | A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05413421 | Phase I | ORIC-944 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05563558 | Phase II | Cabazitaxel + Carboplatin + Pembrolizumab | Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) (PEAPOD_FOS) | Recruiting | ESP | 0 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |
NCT05652686 | Phase I | PT217 | A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Recruiting | USA | 0 |
NCT05691465 | Phase II | lutetium Lu 177 dotatate | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Recruiting | USA | 0 |
NCT05988918 | Phase II | CEP-11981 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | Recruiting | USA | 0 |
NCT06094842 | Phase I | L1CAM-specific CAR+EGFRt+ T cells Bendamustine Cyclophosphamide + Fludarabine | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | Not yet recruiting | USA | 0 |
NCT06406465 | Phase II | Belinostat + Cisplatin + Etoposide | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | Not yet recruiting | USA | 0 |
NCT06613009 | Phase I | IBI3009 | Study of IBI3009 in Subjects With Unresectable, Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Not yet recruiting | AUS | 0 |